Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by jeffm34


T.TH

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Meeting with management

treating advanced cancers should be an advantage for TH1902. A lot of those...

May 6, 2022

T.TH

RE:RE:RE:Yet more on the meeting with management

I think Taimed can find a new European partner.   It is an expensive...

May 6, 2022

T.TH

RE:RE:RE:Board Of Directors

https://www.cbc.ca/amp/1.6434027 Elliott only owns 3.4% of suncor yet they...

April 28, 2022

T.TH

Bladder cancer study

https://www.docwirenews.com/gu-oncology-now/diagnostic-and-therapeutic...

April 27, 2022

T.TH

RE:RE:RE:Some more random thoughts

My science background is pharmacology and pharmacy. I still practice in...

April 27, 2022

T.TH

RE:Some more random thoughts

The bar for approval of TH1902 is actually fairly low. It either has to be...

April 27, 2022

T.TH

RE:RE:RE:RE:RE:RE:Tarveda Therapeutics

The amount of off target accumulation of TH1902 will likely be higher than...

April 25, 2022

T.TH

RE:RE:RE:RE:Tarveda Therapeutics

Actually there are significant comparisons and implications for TH1902. ...

April 24, 2022

T.TH

RE:RE:RE:Tarveda Therapeutics

More info on targeting NT receptors.  NTSR3 (sortilin) may be the better...

April 24, 2022

T.TH

RE:RE:Tarveda Therapeutics

What's more relevant is the work they've done targeting the NT...

April 24, 2022

T.TH

Tarveda Therapeutics

A company with similar technology for cancer. They even did work on a NTSR1...

April 24, 2022

T.TH

RE:RE:Sortilin info

This article has some insight into its distribution on the cell membrane...

April 16, 2022

T.TH

RE:RE:Sortilin info

Only a minor fraction of the sortilin receptors are normally present at the...

April 16, 2022

T.TH

Sortilin info

Lots of information on sortilin available here https://www.proteinatlas.org...

April 15, 2022

T.TH

RE:Amendment to trial design

An additional location has also been added. Mary Crowley cancer research in...

April 15, 2022

T.TH

Amendment to trial design

This appears to have been added into the latest trial design amendment...

April 15, 2022

T.TH

RE:RE:RE:RE:RE:RE:RE:RE:Quick Summary

What might be helpful is the types of cancers the patients in the phase 1a...

April 14, 2022

T.TH

RE:RE:Cash position

Does anyone have any recent examples of what a debt financing of this size...

April 13, 2022

T.TH

Cash position

Now down to 12 month cash runway. Cash required in next financing will be at...

April 13, 2022

T.TH

RE:RE:RE:RE:RE:Fins are out..

European trogarzo sales down 56% from Q1 2021. How long have they been...

April 13, 2022

Featured Company